• +353-1-416-8900(GMT OFFICE HOURS)
  • 1-800-526-8630(US/CAN TOLL FREE)
  • 1-917-300-0470(EST OFFICE HOURS)
Puerto Rico Pharmaceuticals and Healthcare Report Q1 2013 - Product Image

Puerto Rico Pharmaceuticals and Healthcare Report Q1 2013

  • Published: January 2013
  • Region: Puerto Rico
  • 85 pages
  • Business Monitor International

FEATURED COMPANIES

  • Abbott Laboratories
  • Company Profiles
  • Eli Lilly
  • GlaxoSmithKline
  • Johnson & Johnson (J&J)
  • Merck & Co
  • MORE

BMI View:

The outcome of the upcoming elections is expected to assist in shaping the development of Puerto Rico's healthcare and pharmaceutical markets, depending on the direction of the new governor's economic policies. Nevertheless, we do not expect a return to the historically-high annual rates of pharmaceutical spending, especially as the government now covers less than 40% of the territory's overall healthcare spending. In the meantime, the territory will remain an important pharmaceutical and medical devices production base, although its attractiveness has been on the wane for some time now.

Headline Expenditure Projections
- Pharmaceuticals: US$2.81bn in 2011 to US$2.88bn in 2012; +2.5% in local currency terms.

Forecast unchanged from Q412.

- Healthcare: US$11.27bn in 2011 to US$11.67bn in 2012; +3.6% in local currency terms.

Forecast unchanged from Q412.

- Medical devices: US$536mn in 2011 to US$541mn in 2012; +0.9% in local currency terms.

Forecast unchanged from Q412.

Risk/Reward Rating:

Puerto Rico again remains third in our proprietary Pharmaceutical Risk/Reward Ratings (RRRs) matrix for the Americas in READ MORE >

Executive Summary 5

SWOT Analysis 7

Puerto Rico Pharmaceuticals And Healthcare Industry SWOT 7

Pharmaceutical Risk/Reward Ratings 8
Table: Americas Pharmaceutical Risk/Reward Ratings, Q113 8

Rewards 9

Risks 9

Puerto Rico - Market Summary 11

Regulatory Regime 13

Pricing And Reimbursement Issues 14

Tax Incentives 14
Table: Incentives, Benefits And Discounts For Pharmaceutical Manufacturers 16

Trade Accords 17

Industry Developments 18

Epidemiology 18

Healthcare Sector 19

Effects Of US Healthcare Reform 21

Healthcare Financing 22

Healthcare Provision 24

Research & Development 24

Biotechnology 26

Clinical Trials 27

Medical Devices 28

Industry Forecast Scenario 30

Pharmaceutical Market Forecast 30
Table: Pharmaceutical Sales Indicators 2008-2016 31

Healthcare Market Forecast 32
Table: Healthcare Expenditure Indicators 2008-2016 33
Table: Healthcare Governmental Indicators 2008-2016 33
Table: Healthcare Private Indicators 2008-2016 34

Key Growth Factors - Macroeconomic 34

Prescription Drug Market Forecast 36
Table: Prescription Drug Sales Indicators 2008-2016 36

Patented Drug Market Forecast 37
Table: Patented Drug Market Indicators 2008-2016 38

Generic Drug Market Forecast 38
Table: Generic Drug Sales Indicators 2008-2016 39

OTC Medicine Market Forecast 40
Table: OTC Medicine Sales Indicators 2008-2016 41

Pharmaceutical Trade Forecast 41
Table: Exports and Imports Indicators 2008-2016 44

Medical Device Market Forecast 45
Table: Medical Devices Sales Indicators 2008-2016 46

Other Healthcare Data Forecasts 46

Key Risks To BMI's Forecast Scenario 46

Competitive Landscape 48

Pharmaceutical Industry 49
Table: Major International Drugmakers In Puerto Rico 50

Pharmaceutical Production 52

Plant Closures 54
Table: Puerto Rico: Multinational Downscaling 54

Company Developments 55

Pharmaceutical Wholesale 58

Pharmaceutical Retail 58

Company Profiles 61

Pfizer 61

GlaxoSmithKline 63

Merck & Co 65

Abbott Laboratories 67

Novartis 69

Sanofi-Aventis 70

Eli Lilly 71

Johnson & Johnson (J&J) 73

Demographic Outlook 75
Table: Puerto Rico's Population By Age Group, 1990-2020 ('000) 76
Table: Puerto Rico's Population By Age Group, 1990-2020 (% of total) 77
Table: Puerto Rico's Key Population Ratios, 1990-2020 78
Table: Puerto Rico's Rural And Urban Population, 1990-2020 78

Glossary 79

BMI Methodology 81

How We Generate Our Pharmaceutical Industry Forecasts 81

Risk/Reward Ratings Methodology 82

Ratings Overview 82
Table: Pharmaceutical Business Environment Indicators 83

Weighting 84
Table: Weighting Of Components 84

Sources 84

Company Profiles
Pfizer
GlaxoSmithKline
Merck & Co
Abbott Laboratories
Novartis
Sanofi-Aventis
Eli Lilly
Johnson & Johnson (J&J)

Note: Product cover images may vary from those shown

RELATED PRODUCTS

Our Clients

Our clients' logos